Evaxion Biotech A/S (NASDAQ:EVAX – Get Free Report) and BioAtla (NASDAQ:BCAB – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk.
Risk & Volatility
Evaxion Biotech A/S has a beta of -0.02, indicating that its stock price is 102% less volatile than the S&P 500. Comparatively, BioAtla has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500.
Institutional and Insider Ownership
11.0% of Evaxion Biotech A/S shares are held by institutional investors. Comparatively, 77.2% of BioAtla shares are held by institutional investors. 41.6% of Evaxion Biotech A/S shares are held by company insiders. Comparatively, 8.4% of BioAtla shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Evaxion Biotech A/S | 0 | 0 | 2 | 0 | 3.00 |
| BioAtla | 0 | 0 | 4 | 0 | 3.00 |
Evaxion Biotech A/S presently has a consensus target price of $11.00, indicating a potential upside of 198.10%. BioAtla has a consensus target price of $14.50, indicating a potential upside of 281.58%. Given BioAtla’s higher possible upside, analysts plainly believe BioAtla is more favorable than Evaxion Biotech A/S.
Profitability
This table compares Evaxion Biotech A/S and BioAtla’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Evaxion Biotech A/S | N/A | -451.63% | -149.27% |
| BioAtla | N/A | -110.65% | -75.37% |
Valuation & Earnings
This table compares Evaxion Biotech A/S and BioAtla’s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Evaxion Biotech A/S | $70,000.00 | 213.49 | -$22.12 million | ($6.76) | -0.55 |
| BioAtla | $250,000.00 | 731.12 | -$123.46 million | ($2.59) | -1.47 |
Evaxion Biotech A/S has higher earnings, but lower revenue than BioAtla. BioAtla is trading at a lower price-to-earnings ratio than Evaxion Biotech A/S, indicating that it is currently the more affordable of the two stocks.
Summary
BioAtla beats Evaxion Biotech A/S on 9 of the 12 factors compared between the two stocks.
About Evaxion Biotech A/S
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.
About BioAtla
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and head and neck cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
Receive News & Ratings for Evaxion Biotech A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion Biotech A/S and related companies with MarketBeat.com's FREE daily email newsletter.
